Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > So do we assume the JNJ option expired?

<< Previous

Bullboard Posts

Next >>

Comment by G1945Von Jan 29, 2023 10:13am

152 Views

Post# 35252587

RE:RE:RE:RE:So do we assume the JNJ option expired?

Boomskid wrote: The latest MD&A has details, G1945V, on Page 10.

jd

MD&A dated January 19, 2023:

"On April 11, 2022, the Company entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson. Under the terms of the agreement, the Company received a non-refundable, upfront payment of US$100,000. In addition, the Company will receive milestone payments based on the achievement of the milestone events defined in the agreement. The agreement is effective until the earlier of (i) completion of the research, or (ii) January 31, 2023. Janssen will have the option to research, develop and commercialize novel products based on the Company’s xB 3 technology. The agreement was facilitated by Johnson & Johnson Innovation."

G1945V